Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with Sickle Cell Disorder

Author(s): Wambebe C, Khamofu H, Momoh JA, Ekpeyong M, Audu BS, et al.


The study was undertaken to determine the safety and efficacy of NIPRISAN, a phytomedicine, developed for the management of patients with Sickle Cell Disorder (SCD). The study design is a placebo-controlled double blind cross-over trial. Eighty-two (82) patients with SCD were recruited and randomised into two groups. An initial 4 month pre-trial study was undertaken to determine the similarity of the groups. The main study was conducted over a twelve-month period with crossover at six months. Safety of the drug was assessed clinically and biochemically. NIPRISAN significantly (P < 0.01) reduced the frequency of SCD crisis associated with severe pains. Acute toxicity to the liver assessed by the activities of liver enzymes, indicate that NIPRISAN is safe. Renal function assessed by the serum levels of creatinine and blood urea nitrogen remained normal. Both the clinical and laboratory results of the present phase IIB (pivot) clinical study suggest that NIPRISAN is a safe and efficacious phytomedicine for the management of patients with Sickle Cell Disorder.

Similar Articles

In vitro antisickling activities and phytochemical evaluation of Plumbagozeylanica and Uvariachamae

Author(s): Olufunmilayo EA, Adelodun LK, Oladimeji PR, Lateef SK

Sickle cell disease in Africa

Author(s): Diallo D, Tchernia G

A Comprehensive Review on Biological Activities of P-Hydroxy Benzoic Acid and Its Derivatives

Author(s): RohiniManuja, ShikhaSachdeva, Akash Jain, Jasmine Chaudhary

Schiff base adducts of hemoglobin

Author(s): Zaugg RH, Walder JA, Klotz IM

Vanillin, a potential agent for the treatment of sickle cell anemia

Author(s): Abraham DJ, Mehanna AS, Wireko FC, Whitney J, Thomas RP, et al.

Chromatographic analysis of antisickling compounds in Zanthoxylum species

Author(s): Elujoba AA, Nagels L, Sofowora A, VanDongen W

Alternative aspirins as antisickling agents: acetyl-3,5-dibromosalicylic acid

Author(s): Walder JA, Zaugg RH, Iwaoka RS, Watkin WG, Klotz IM

NMR study of the sites of human hemoglobin acetylated by aspirin

Author(s): Xu AS, Macdonald JM, Labotka RJ, London RE

Design, synthesis, and testing of potential antisickling agents

Author(s): Abraham DJ, Gazze DM, Kennedy PE, Mokotoff M

Antisickling properties of divanilloylquinic acids isolated from Fagarazanthoxyloides Lam

Author(s): Ouattara B, Jansen O, Angenot L, Guissou IP, Frédérich M, et al.